Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06008626
Other study ID # 11515
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 12, 2023
Est. completion date March 31, 2029

Study information

Verified date April 2024
Source Cryosa, Inc.
Contact Kristine Selander
Phone 763-267-3202
Email kselander@cryosa.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, multicenter, non-randomized single-arm safety and performance study to collect data to evaluate the safety of the Cryosa procedure to treat obstructive sleep apnea (OSA) in patients with moderate to severe OSA. The study will also evaluate the chronic performance of the Cryosa system and collect clinical measures for therapy effectiveness that will be used to demonstrate safety and effectiveness in the next clinical study.


Description:

The study will treat 25 subjects enrolled at up to 10 sites in the United States. Enrollment is competitive but each site will be limited to 15 subjects treated.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date March 31, 2029
Est. primary completion date September 29, 2024
Accepts healthy volunteers No
Gender All
Age group 22 Years to 70 Years
Eligibility Inclusion Criteria: 1. Age 22 - 70 years 2. Likely suffer moderate to severe OSA based on history and physical or have an established diagnosis of moderate to severe OSA (AHI = 15) based on a prior sleep study. PSG will be performed after enrollment, or an acceptable PSG performed within 3 months of enrollment is required, to verify a) AHI = 15 b) mixed and central apneas total = 25% of apneas, and c) SpO2 must be = 70% for = 90% of sleep time for continued eligibility. 3. Not able to use, refuse to use or intolerant of Positive Airway Pressure (PAP) or Mandibular Advancement Device (MAD) 4. BMI of = 40 kg/m2 at enrollment 5. Is geographically stable and in close proximity to the site 6. Able and willing to provide written consent to participate in the study Exclusion Criteria: 1. Contraindication to general anesthesia or in the opinion of the Investigator would not be able to tolerate the procedure, including intubation during the procedure or in response to an adverse event 2. Severe maxillary mandibular insufficiency that in the opinion of the investigator thought to be the primary cause of OSA 3. Obvious severe fixed upper airway obstructions (tumors, polyps, nasal obstruction) 4. Previous surgery within 12 weeks of scheduled procedure performed on the soft tissue of the upper airway (e.g., uvula, soft palate, or tonsils). 5. Oral cancer or non-healing oral wounds 6. Prior sleep surgeries, including tongue base reduction, UPPP and hypoglossal nerve stimulation. 7. History of radiation therapy to neck or upper respiratory tract 8. Surgical resection for cancer or congenital malformations in the larynx, tongue, or throat (with exception of tonsillectomy and/or adenoidectomy) 9. History of cold urticaria 10. History of hospitalization with mechanical ventilation due to COVID-19 per investigator discretion 11. Resistant hypertension defined as a blood pressure that remains above goal despite concurrent use of three antihypertensive agents of different classes taken at maximally tolerated doses 12. Neuromuscular disease or other neurologic deficits (for example multiple sclerosis, muscular dystrophy, Parkinson's disease, transient ischemic attack, epilepsy or cerebrovascular accident) 13. Diagnosis of any moderate to severe congestive obstructive pulmonary disease (COPD) 14. Active, severe pulmonary vascular disease (for example pulmonary arterial hypertension or pulmonary embolism) 15. Untreated, active thyroid disease such as Hashimoto Thyroiditis that may cause angioedema or enlargement of the tongue 16. History of angioedema of the tongue 17. Uncontrolled Diabetes (including Diabetes Mellitus [DM] or Insulin Dependent Diabetes Mellitus [IDDM]) with HbA1c >9. 18. Currently receiving treatment for severe cardiac valvular dysfunction, NYHA Class III or IV heart failure, unstable angina or recent (< 12 months) myocardial infarction or severe cardiac arrhythmias 19. Subjects with bleeding event, known bleeding diathesis, impaired immunity for any reason, or heart attack or stroke within the last 12 months 20. Clinical evidence of severe renal failure (Stage 4 or 5) undergoing dialysis or expected to institute dialysis within 6 months 21. History or current clinical evidence of TIA or stroke or muscular dysfunction 22. Current smoker (= 1 pack/day) 23. Presence of occupational shift work or anticipation of shift changes during the next 2 years 24. Subject has sleep hygiene behavior that is likely to interfere with measurement outcomes during PSG and/or HSAT 25. Known active substance use disorder 26. Other severe sleep disorders that in the opinion of the investigator, confound functional assessments of sleepiness such as narcolepsy with cataplexy, severe insomnia/insomnia secondary to chronic pain, PTSD 27. Patients taking any of the following medication that could affect study endpoints: benzodiazepines, Z-drugs (zolpidem and eszopiclone) opiates, antipsychotics (neuroleptics), phenothiazines, and prescription stimulants (including Sunosi, Provigil, and Nuvigil) 28. Active psychiatric disease (psychotic illness, major depression, or acute anxiety attacks) which prevents subject's ability to meet study requirements and ability to provide study consent 29. Females who are pregnant or females of childbearing age with intention to become pregnant during the study period (= 3 months from treatment date) 30. Any other reason the investigator deems subject is unfit for participation in the study 31. Subject currently participating in other premarket investigational studies unless approved by Sponsor in writing

Study Design


Intervention

Device:
Cryosa Procedure
Cryotherapy

Locations

Country Name City State
United States Albany ENT & Allergy Services Albany New York
United States Specialty Physician Associates Bethlehem Pennsylvania
United States University of Tennessee Health Sciences Center Memphis Tennessee
United States University of Miami Miami Florida
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Cryosa, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Home Sleep Apnea Testing (HSAT) - Apnea-Hypopnea Index (AHI4) Two nights of testing will be collected, and the average of the two nights will be used to evaluate the change in AHI4 after treatment compared to baseline. 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure
Other Home Sleep Apnea Testing (HSAT) - Oxygen Desaturation Index (ODI) Two nights of testing will be collected, and the average of the two nights will be used to evaluate the change in ODI sleep metrics after treatment compared to baseline. 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure
Other Home Sleep Apnea Testing (HSAT) - Oxygen Saturation (SpO2) Two nights of testing will be collected, and the average of the two nights will be used to evaluate the change in SpO2 sleep metrics after treatment compared to baseline. 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure
Other Home Sleep Apnea Testing (HSAT) - Hypoxic Burden Two nights of testing will be collected, and the average of the two nights will be used to evaluate the change in hypoxic burden sleep metrics after treatment compared to baseline. 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure
Other Home Sleep Apnea Testing (HSAT) - Snoring Two nights of testing will be collected, and the average of the two nights will be used to evaluate the change in snoring episodes sleep metrics after treatment compared to baseline. 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure
Primary Incidence of Serious Procedure or Device/ Treatment Related Events Safety will be assessed by evaluating all serious procedure- or device/treatment-related events occurring in the first 90 days post-procedure.
Adverse events (AE), both serious and non-serious, related and unrelated, will be collected from all subjects enrolled for the duration of the study.
First 90 days post-procedure
Secondary Sleep Testing Quantify the effect of the Cryosa procedure in reducing the severity of OSA post-procedure by evaluating the change from baseline in the apnea hypopnea index (AHI4) with polysomnography (PSG) testing. 6 Month Follow-up Visit
Secondary Patient Reported Outcomes (PRO) Efficacy Measures - Epworth Sleepiness Survey (ESS) Evaluate change in daytime sleepiness after treatment compared to baseline. 30 Days, 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure
Secondary Patient Reported Outcomes (PRO) Efficacy Measures - Functional Outcomes of Sleep Questionnaire (FOSQ) Evaluate the change of impact of daytime sleepiness on activities of daily living after treatment compared to baseline. 30 Days, 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure
Secondary Patient Reported Outcomes (PRO) Safety Measures - Pain Numeric Scale (NRS) Evaluate oropharyngeal pain metrics after treatment compared to baseline. 7 Days, 30 Days, 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure
Secondary Patient Reported Outcomes (PRO) Safety Measures - Eating Assessment Tool (EAT-10) Evaluate change in swallowing metrics after treatment compared to baseline. 7 Days, 30 Days, 90 Days, 6 Months, 12 Months, 18 Months and 24 Months Post-procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05489562 - Use of Intraoral Suction and Its Effects on Obstructive Sleep Apnea N/A
Recruiting NCT05717959 - Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device N/A
Completed NCT03940781 - Effects of Rehabilitation for Patients With Obstructive Sleep Apnea N/A
Completed NCT03122639 - Endothelial Function in Obstructive Sleep Apnea Early Phase 1
Recruiting NCT05289063 - Vascular Endothelial Dysfunction in Sleep Apnea Phase 1
Not yet recruiting NCT05268471 - Cost-effectiveness Analysis and Conditional Response to the Effect of Positional Devices in Obstructive Sleep Apnea N/A
Active, not recruiting NCT04864652 - Safety and Dosing Study of the CHILLS Cryotherapy for the Treatment of OSA N/A
Enrolling by invitation NCT05433883 - The Relationship Between Obstructive Sleep Apnea and Alzheimer's Disease: Evidence and Effectiveness N/A
Recruiting NCT06103630 - Efficacy of Oropharyngeal Exercises for Patients With Obstructive Sleep Apnea Using Mandibular Advancement Device N/A
Recruiting NCT06283095 - Management of Obstructive Sleep Apnea Syndrome by Expansion Palatoplasty N/A
Completed NCT03156283 - SleepWell24: An Innovative Smartphone Application to Improve PAP Adherence N/A
Completed NCT03362385 - OSA-ACS Project: Association of OSA and CPAP Therapy With Outcomes in ACS Patients
Recruiting NCT06447818 - Changes in Difficult Airway Markers After Surgery for Obstructive Sleep Apnoea Syndrome
Completed NCT04643782 - Comparative Study of the ANNEā„¢ One System to Diagnose Obstructive Sleep Apnea N/A
Recruiting NCT03463785 - Does Race Make a Difference in Obstructive Sleep Apnea?
Recruiting NCT03618719 - Impact of Intermittent Hypoxia on the Function of the Phagocytes
Completed NCT03048604 - BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnoea (BLAST OSA) N/A
Recruiting NCT05290350 - Long COVID-19 Fatigue and Obstructive Sleep Apnea
Recruiting NCT05739617 - Comprehensive Respiratory Training Exercise Program in Obstructive Sleep Apnea N/A
Completed NCT03980158 - Change in Tongue Strength and Fatigue After Upper Airway Stimulation Therapy